Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEACE III: Enzalutamide vs. Enzalutamide + Radium-223 in Bone Metastatic CRPC
NCT02194842Phase 3Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Oct 2015
- Primary completion
- Feb 2024
- Modality
- Radiopharmaceutical
- Countries
- 12
01
Overview
A Phase 3 trial of radium-223 dichloride in prostate cancer (PCa), sponsored by European Organisation for Research and Treatment of Cancer. Started Oct 2015; status: active, not recruiting.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02194842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02194842.